THE FUTURE IS NOW

FDA APPROVALS
BREAKTHROUGH TREATMENTS IN CLINICAL TRIALS
PHARMACEUTICAL INVESTMENTS
DISCOVERY RESEARCH IN THE LAB
NEW HOPE FOR CANCER CARE

2017

ALLIANCE FOR CANCER GENE THERAPY
ALLIANCE FOR CANCER GENE THERAPY

FOUNDED in 2001 by Barbara and Edward Netter, ACGT is the only charitable organization in the nation dedicated exclusively to funding cell and gene therapies for cancer.

OUR MISSION is to support revolutionary scientific research into the causes, treatment and prevention of all types of cancer, using cells and genes as medicine.

OUR COMMITMENT is to identify, fund and monitor innovative research studies and trials that meet a rigorous set of scientific standards and have the potential to treat cancers of all types in the foreseeable future.

www.acgtfoundation.org
This has been a landmark year for ACGT. The FDA approved the first cancer gene therapy in August, a CAR T immunotherapy treatment for relapsed pediatric leukemia patients that received early funding from ACGT. Approval for a modified version of this treatment for adult leukemia patients is expected before the end of the year. In October, the FDA approved an immunotherapy treatment for diffuse large B cell lymphoma. The momentum has begun and we look forward to more cell and gene therapies making their way from the laboratory to patients in the months ahead.

While we are thrilled to see these therapies move from bench to bedside, we know we still have work to do. Despite the success of CAR T therapies with blood cancers, solid tumors present a different set of challenges. ACGT is focusing on this area of need by supporting three clinical investigators who are developing unique approaches to treating glioblastoma, ovarian cancer and sarcoma. Our Scientific Advisory Council, comprised of some of the most seasoned and respected names in the business, will continue to identify the most innovative scientists so we can help save more lives.

Barbara and Edward Netter’s vision in forming ACGT in 2001 was ultimately to fund the development of safe, nontoxic treatments for patients. We would not be at this inflection point in 2017 without your passionate commitment as donors. We value your partnership as we help drive the next generation of cancer cell and gene therapies. The future is now and you won’t want to miss the ride.

John Walter  
CEO & President, Alliance for Cancer Gene Therapy

“We would not be at this inflection point in 2017 without your passionate commitment as donors.”
16 Years ago, when Barbara and Edward Netter’s daughter-in-law succumbed to breast cancer, they sought out state-of-the-art research into better forms of treatment. When they learned about gene therapy, they knew there would soon be a paradigm shift toward molecular medicine – treatments that more effectively destroy cancer with less toxicity.

Alliance for Cancer Gene Therapy was founded to accelerate progress and fund the best research at the most prestigious institutions developing cell and gene therapies for cancer. Edward Netter’s resources and business acumen formed the basis for a determined effort to find a better way to treat cancer and his vision is now being realized.

This year, the first cancer gene therapy treatment approved by the FDA is a therapy that was developed in a laboratory study in 2004 with partial funding from ACGT. There are many more cell and gene therapies now in clinical trials. Leading pharmaceutical companies are also investing in what promises to transform the way we treat cancer.

“*When other organizations, including the NIH, considered gene therapy too risky, ACGT believed in the science and funded us when no one else would. ACGT really kept us going and kept the research alive. Without them, we wouldn’t have had a clinical trial and I don’t think we’d be where we are today.*”

Dr. Carl June
University of Pennsylvania
Lead Investigator, CAR T Therapy for Leukemia
ACGT Research Fellow/Scientific Advisory Council Member
THE FUTURE IS HAPPENING NOW

When Doug Olson was diagnosed in 1996 with chronic lymphocytic leukemia (CLL) he learned that it was a slow growing cancer, but that there was no cure. By 2010, the cancer had become resistant to standard chemotherapy and more than 50 percent of his bone marrow was cancer cells. Fortunately, Doug’s physician, Dr. David Porter, was a principal investigator in the CAR T immunotherapy trial led by Dr. Carl June at the University of Pennsylvania. Doug was patient #2 in this breakthrough clinical trial that used his own reprogrammed T cells to kill cancer cells – a study funded partially by ACGT. In less than four weeks, no detectable cancer was found anywhere in Doug’s body. He has been in remission ever since with no side effects. FDA approval is expected for this CAR T gene therapy for adult CLL patients by the end of the year.

Today, and for the foreseeable future, Doug is able to enjoy his life with his wife, their four children and three grandchildren, because of gene therapy.

“I can say without hesitation I am alive today because ACGT supports medical science on the front lines of cell and gene therapies for cancer.”

Dr. Doug Olson
Leukemia Survivor
TREATMENTS AND TRIALS
BREAKING NEW GROUND

The FDA JUST APPROVED the first gene therapy for relapsed pediatric B cell leukemia. The CAR T gene therapy, now known as Kymriah, received funding from ACGT in 2004 while first in development by Dr. Carl June at the University of Pennsylvania. Novartis ultimately partnered with the Penn Medicine team to fund clinical trials that showed an exceptional 83 percent remission rate among pediatric and young adult patients with relapsed, refractory acute lymphoblastic leukemia (ALL). With this FDA approval, 35 cancer centers around the country will make this personalized therapy readily available to pediatric ALL patients who have no other treatment options.

A new immunotherapy treatment for diffuse large B cell lymphoma was also approved by the FDA in October. Immunotherapy drugs like Keytruda [Merck] are now offered as first choices for select lung cancers and used in combination with chemotherapy. Patients are living longer.

Three groundbreaking trials underway for glioblastoma, a deadly brain cancer, by ACGT researchers:
- Virotherapy using a Maraba virus, based on research by Dr. John Bell, Turnstone Biologics.
- Virotherapy using a Herpes simplex virus, research by Dr. Antonio Chiocca, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute.
- Immunotherapy to prevent cancer recurrence, research by Dr. Laurence Cooper, Ziopharm.

“<i>The most exciting advancement is cell and gene therapy – to manipulate cells outside the body, put genes in them, and return them to the body so these cells can sniff out the cancer and destroy them.</i>”

Dr. Laurence Cooper
CEO, Ziopharm
ACGT Research Fellow
Rachel, at age 11, was diagnosed with acute lymphoblastic leukemia [ALL]. After a standard two-year treatment protocol, she entered high school in remission. However, in 2015, just shy of the five-year mark, Rachel relapsed. This time, her immune system collapsed and she spent 100 days in the hospital, followed by four months of intensive physical therapy. When her cancer returned a year later, options had run out. On the advice of her doctors, she entered Dr. Carl June’s CAR T GENE THERAPY clinical trial in January at Children’s Hospital of Philadelphia (CHOP), and returned home soon after without severe side effects. She resumed college classes and has remained cancer free ever since.

“The six weeks of treatment went better than I could have ever imagined. My reaction was so minor I was able to explore Philadelphia with friends and family. Now, I check in monthly with my home clinic and return to CHOP for quarterly visits. If these T cells stick around, as hoped, I will have a forever remission!”

Rachel Elliott
Leukemia Survivor

CAR T cell therapy, a form of gene therapy, harnesses the body’s immune system by removing a patient’s own T cells, re-engineering them and returning them to the body to target the markers found on cancer cells, leaving healthy cells alone. This has been hugely successful in blood cancers and ACGT is now funding this type of research for solid tumors.
Virotherapy first made news in 2015 when a trial at Duke University using a modified polio virus effectively destroyed glioblastoma, a deadly brain cancer. Half the patients, in advanced stages, went into remission. In other studies supported by ACGT, a measles virus destroyed blood cancer, and a Maraba virus, related to rabies, reduced the size and spread of melanoma, lung and colon cancers, as well as select brain tumors.

The FDA has approved the first virotherapy drug, Imlygic [Amgen], to treat recurrent melanoma, with the hope of extending lives and preventing relapse.

"Viral therapy is a powerful 1-2 punch – the virus attacks the tumor and the immune system comes in to finish the job."

Dr. John Bell
Turnstone Biologics
ACGT Research Fellow/
Scientific Advisory Council Member
CHECKPOINT INHIBITORS: BYPASSING RESISTANCE TO TREATMENT

Cancer cells are determined to protect their existence. They contain proteins that allow them to hide from our immune system. The proteins are called CHECKPOINT INHIBITORS. They are a major obstacle to the immune system’s ability to detect and destroy many cancers. Scientists are also learning how to make sure the immune system does not attack healthy cells.

The newest approach combines immunotherapies with chemotherapy to shut down inhibitors and attack the cancer, after which the immune system stands guard to protect against recurrence. Once immunotherapies reach full development and approvals, they will do the job on their own so side effects in the future will be minimized.

“Right now we are extending lives using cell and gene therapies, and soon, based on new research, clinical trials, and advanced technology, these therapies will take the lead as frontline therapies and save even more lives.”

Dr. Joseph Glorioso
Chairman
ACGT Scientific Advisory Council

An analysis of 4,846 advanced melanoma patients treated with one checkpoint inhibitor – Bristol-Myers Squibb Co.’s Yervoy – found that 21% were still alive three years later. More than 1,000 people, experts say, almost certainly would have died otherwise.
A CANCER VACCINE

Like many deadly diseases – polio, smallpox, tuberculosis – cancer may someday be manageable or extinct.

Unlike other vaccines that introduce live pathogens into the body, a CANCER VACCINE may introduce modified genetic material to stimulate the immune system to take action. Scientists have also identified an enzyme present in many cancers that may serve as a beacon for the body’s immune system, making treatment even more effective and with minimal or no side effects.

“Every day there is a progress report from the laboratory, more patients are enrolled in clinical trials, and the pharmaceutical industry is continuing to expand research and development into genetic medicines for cancer. The future is rapidly approaching.”

John Walter
ACGT CEO & President
GENE EDITING IS THE NEXT FRONTIER

Medical scientists may soon be able to alter, eliminate or modify genes to neutralize cancer or other diseases before or after they strike. Even a minor change to the DNA, and its internal molecular structure, can make a major difference in health and longevity and this can be accomplished at any point in the human lifespan.

CRISPR [Clustered Regularly Interspaced Short Palindromic Repeats] is essentially a molecular medical “scissor” that cuts and pastes a portion of the genetic code to eliminate disease. The first step is to use the process in conjunction with immunology to hit cancer from start to finish.

“We may be nearing the beginning of the end of genetic diseases.”

Jennifer Doudna
Professor of Chemistry and Molecular and Cell Biology
University of California, Berkeley and CRISPR Pioneer

Dr. Clodagh O’Shea, an ACGT Research Fellow at the Salk Institute, recently led a team to model the internal structure of DNA to permit more direct modification of the genetic code.
2017 GRANT AWARDS
MEDICAL SCIENTISTS BREAKING NEW GROUND AND/OR LEADING TRIALS

CLINICAL INVESTIGATORS

Noriyuki Kasahara, MD, PhD
Professor, Cell Biology and Pathology
University of Miami
Cancer Target: Glioblastoma

Dr. Kasahara will use his Investigator Award to advance a clinical trial for a virotherapy for deadly brain cancer. Using a modified virus to deliver chemotherapy directly into cancer cells, these “suicide genes” continue to replicate to prevent recurrence. The grant takes off from his successful laboratory research.

Seth Pollack, MD
Assistant Professor
Fred Hutchinson Cancer Research Center,
University of Washington
Cancer Target: Sarcoma

Dr. Pollack’s Clinical Investigator Grant will further his research using immunology to target this rare form of cancer that grows in connective tissue - cells that support other body tissues such as those in bones, muscles, tendons, etc. This first level trial will deploy two types of genetically engineered T cells to target the cancer to assess the efficacy and safety.
Daniel Powell, PhD  
*Associate Professor, Pathology and Laboratory Medicine*  
University of Pennsylvania Perelman School of Medicine  
Cancer Target: Ovarian Cancer

Dr. Powell’s research focuses on the development of innovative strategies including adoptive immunotherapy using chimeric antigen receptors (CAR T) cells. Powell’s Clinical Investigator grant will be used to enroll ovarian cancer patients in a new clinical trial. Immune system killer T cells will be developed outside the body and reinserted to establish an offense against the disease and a defense against recurrence.

**YOUNG INVESTIGATORS**

**Greg Delgoffe, PhD**  
*Assistant Professor, Immunology*  
University of Pittsburgh  
Cancer Target: Melanoma

A grant to Dr. Delgoffe will expand on his previous immunotherapy research for melanoma. Using an approach proven successful with blood cancers, but yet to be refined for solid cancers, this study seeks to bypass the cancer’s natural resistance to treatment and establish “super soldier” T cells at the tumor site to bolster a positive, long-term response.

**Marco Gallo, PhD**  
*Assistant Professor*  
University of Calgary  
Cancer Target: Glioblastoma

Dr. Gallo will use his grant to advance research into the most common and incurable brain cancer in adults. These tumors contain a select set of cancer stem cells responsible for both growth and recurrence, which often successfully evade therapeutic intervention. Using a protein that is able to alter the patient’s DNA architecture, he hopes to unravel this cancer stem cell dominance to effectively treat the cancer.
### 16 YEARS OF PROGRESS

**ACGT ACHIEVEMENT HIGHLIGHTS**

<table>
<thead>
<tr>
<th>Year</th>
<th>Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2017</strong></td>
<td></td>
</tr>
</tbody>
</table>
| • First Gene Therapy treatment for cancer receives FDA approval in August; ACGT provided early research funding  
| • ACGT still the only non-profit in the nation dedicated exclusively to cancer cell and gene therapy  
| • 55 grants totaling over $28 million awarded: $14.0 million to Young Investigators, $14.2 million to Clinical Translation Investigators |
| **2016** |  
| • ACGT hosts Scientific Symposium  
| • 10th anniversary of Swim Across America Greenwich-Stamford benefiting ACGT  
| • Clinical Award for Sarcoma Research co-funded by Wendy Walk and SAA |
| **2011** |  
| • ACGT researchers destroy lymphoma cells in human trials reaching tipping point for immunotherapy  
| • Biotech and pharmaceutical companies begin to form partnerships with researchers to accelerate progress |
| **2006** |  
| • First Lifetime Achievement Award presented to Dr. Judah Folkman at ACGT’s Fifth Anniversary Gala  
| • Swim Across America selects ACGT as sole beneficiary of 2007 Greenwich-Stamford Inaugural Swim Event  
| • ACGT meets the extensive standards of America’s most experienced charity evaluator: the BBB Wise Giving Alliance |
| **2004** |  
| • ACGT awards first clinical translational grants for immunotherapy to Dr. Carl June at University of Pennsylvania and Dr. Michel Sadelain at Memorial Sloan Kettering |
| **2001** |  
| • Phase 1 of Human Genome Map completed  
| • Alliance for Cancer Gene Therapy founded by Barbara and Edward Netter, to promote cell and gene therapy research for cancer |
## CONDENSED STATEMENTS OF ACTIVITIES

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support and revenue:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$893,125</td>
<td>$1,263,856</td>
</tr>
<tr>
<td>Special Events</td>
<td>437,669</td>
<td>0</td>
</tr>
<tr>
<td>Contributed services</td>
<td>674,007</td>
<td>461,802</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>90,116</td>
<td>101,788</td>
</tr>
<tr>
<td>Realized and unrealized gains on investments, net</td>
<td>494,223</td>
<td>(362,703)</td>
</tr>
<tr>
<td>Other income</td>
<td>232,370</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td>$2,821,510</td>
<td>$1,464,743</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research grants and awards</td>
<td>1,070,485</td>
<td>1,626,508</td>
</tr>
<tr>
<td>Management and general</td>
<td>297,493</td>
<td>219,584</td>
</tr>
<tr>
<td>Fundraising</td>
<td>208,524</td>
<td>154,222</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>$1,576,502</td>
<td>$2,000,314</td>
</tr>
<tr>
<td>Increase (decrease) in total net assets</td>
<td>$1,245,008</td>
<td>(535,571)</td>
</tr>
<tr>
<td>Total net assets at beginning of year</td>
<td>$3,322,088</td>
<td>3,857,659</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS AT END OF YEAR</strong></td>
<td>$4,567,096</td>
<td>$3,322,088</td>
</tr>
</tbody>
</table>

## CONDENSED STATEMENTS OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,604,418</td>
<td>$1,259,779</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>4,338,812</td>
<td>3,861,376</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>89,200</td>
<td>0</td>
</tr>
<tr>
<td>Other assets</td>
<td>14,721</td>
<td>10,633</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$6,047,151</td>
<td>$5,131,788</td>
</tr>
<tr>
<td><strong>Liabilities and net assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants payable</td>
<td>$1,415,118</td>
<td>$1,753,299</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>64,937</td>
<td>56,401</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>$1,480,055</td>
<td>$1,809,700</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>$4,567,096</td>
<td>$3,322,088</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$6,047,151</td>
<td>$5,131,788</td>
</tr>
</tbody>
</table>

Alliance for Cancer Gene Therapy, Inc.’s complete financial statements are available upon request.
### ACGT RESEARCH FELLOWS

Young Investigator Grants award $250,000-$500,000. Clinical Translation Grants award $500,000-$1,000,000. Applications are peer-reviewed and progress-monitored by ACGT’s Scientific Advisory Council.

#### 2017

- **Noriyuki Kasahara, MD, PhD**  
  Institution: University of Miami  
  Focus: Glioblastoma

- **Daniel Powell, PhD**  
  Institution: University of Pennsylvania  
  Focus: Ovarian Cancer

- **Seth Pollack, MD**  
  Institution: Fred Hutchinson Cancer Research Center  
  Focus: Sarcoma

#### 2016-17

- **Greg Delgoffe, PhD**  
  Institution: University of Pittsburgh School of Medicine  
  Focus: Melanoma

- **Marco Gallo, PhD**  
  Institution: University of Calgary  
  Focus: Brain

- **Yvonne Chen, MS, PhD**  
  Institution: University of California, Los Angeles  
  Focus: Lymphoma/Leukemia

- **Brent Hanks, MD, PhD**  
  Institution: Duke University Medical Center  
  Focus: Melanoma

- **Samuel G. Katz, MD, PhD**  
  Institution: Yale University Medical School  
  Focus: Solid Tumors  
  Award: Swim Across America Award

#### 2015-16

- **Crystal Mackall, MD**  
  Institution: Stanford University School of Medicine  
  Focus: Osteosarcoma  
  Award: Wendy Walk/SAA

- **Meenakshi Hegde, MD**  
  Institution: Baylor College of Medicine  
  Focus: Melanoma

- **Christopher Jewell, PhD**  
  Institution: University of Maryland, College Park  
  Focus: Lymphatic Systems

- **John Bell, PhD**  
  Institution: Ottawa Hospital Research Institute  
  Focus: Brain Cancer  
  Award: Swim Across America Award

#### 2014-15

- **Arnob Banerjee, MD, PhD**  
  Institution: University of Maryland School of Medicine  
  Focus: Blood Cancer  
  Award: Swim Across America Award

- **Fan Yang, PhD**  
  Institution: Stanford University School of Medicine  
  Focus: Brain Cancer  
  Award: Swim Across America Award

- **Douglas Mahoney, PhD**  
  Institution: University of Calgary  
  Focus: Breast Cancer

- **Alexander Stegh, PhD**  
  Institution: Northwestern University  
  Focus: Brain Cancer

- **Herbert J. Zeh, III, MD, FACS**  
  Institution: University of Pittsburgh  
  Focus: Pancreatic Cancer

#### 2013-14

- **Yvonne Chen, MS, PhD**  
  Institution: University of California, Los Angeles  
  Focus: Lymphoma/Leukemia  
  Award: Swim Across America Award

- **Michael Z. Lin, MD, PhD**  
  Institution: Stanford University  
  Focus: Brain/Breast Cancer

#### 2012-13

- **Steve Thorne, PhD**  
  Institution: University of Pittsburgh  
  Focus: Breast/Ovarian Cancer

#### 2011

- **Hui Hu, PhD**  
  Institution: University of Alabama  
  Focus: Ovarian Cancer

- **Nabil Ahmed, MD, MPH**  
  Institution: Baylor College of Medicine  
  Focus: Brain Cancer

- **Glenn Dranoff, MD**  
  Institution: Dana Farber/ Harvard Cancer Center  
  Focus: Leukemia

- **Thomas Kipps, MD, PhD**  
  Institution: Moores Cancer Center, University of California, San Diego  
  Focus: Lymphoma/Leukemia  
  Award: Swim Across America Award

- **Michael Z. Lin, MD, PhD**  
  Institution: Stanford University  
  Focus: Brain/Breast Cancer

#### 2009

- **Carl June, MD**  
  Institution: University of Pennsylvania Abramson Cancer Center  
  Focus: Ovarian Cancer  
  Award: The Joan Miller & Linda Bernstein Ovarian Cancer Award
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Institution</th>
<th>Focus</th>
<th>Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Antonio E. Chiocca, MD, PhD</td>
<td>Harvard Medical School</td>
<td>Brain Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ronald Levy, MD</td>
<td>Stanford University</td>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clodagh O’Shea, PhD</td>
<td>Salk Institute for Biological Studies</td>
<td>Breast Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Khalid Shah, PhD, MSc</td>
<td>Harvard Medical School, Massachusetts General Hospital</td>
<td>Brain Cancer</td>
<td>Swim Across America Award</td>
</tr>
<tr>
<td>2006</td>
<td>Roberto Cattaneo, PhD</td>
<td>Mayo Clinic College of Medicine</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>George Coukos, MD, PhD</td>
<td>University of Pennsylvania Abramson Cancer Center</td>
<td>Ovarian/Peritoneal Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maciej S. Lesniak, MD</td>
<td>University of Chicago</td>
<td>Brain Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kah-Whye Peng, PhD</td>
<td>Mayo Clinic Cancer Center</td>
<td>Multiple Myeloma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eckhard Podack, MD, PhD</td>
<td>University of Miami Miller School of Medicine</td>
<td>Lung Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harald Sauthoff, MD</td>
<td>New York University</td>
<td>Breast/Lung Cancer</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Biao He, PhD</td>
<td>University of Georgia</td>
<td>Breast Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas J. Kipps, MD, PhD</td>
<td>Moores Cancer Center, University of California, San Diego</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyam I. Levitsky, MD</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miguel Sena-Esteves, PhD</td>
<td>University of Massachusetts Medical School</td>
<td>Brain Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Koji Tamada, MD, PhD</td>
<td>University of Maryland (through 2008)</td>
<td>Lymphatic Systems</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yiping Yang, MD, PhD</td>
<td>Duke University Medical Center</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xianzheng Zhou, MD, PhD</td>
<td>New York Medical College</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Chien-Fu Hung, PhD</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Ovarian Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mukesh Jain, MD, FAHA</td>
<td>Case Western Reserve University</td>
<td>Metastatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carl H. June, MD</td>
<td>University of Pennsylvania Abramson Cancer Center</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suzie Pun, PhD</td>
<td>University of Washington</td>
<td>Metastatic Cancer</td>
<td>Patricia Zoch Tate Award</td>
</tr>
<tr>
<td></td>
<td>Michel Sadelain, MD, PhD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jian Yu, PhD</td>
<td>University of Pittsburgh School of Medicine, Hillman Cancer Center</td>
<td>Lung Cancer</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Laurence Cooper, MD, PhD</td>
<td>University of Texas, MD Anderson Cancer Center</td>
<td>Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Timothy Lane, PhD</td>
<td>University of California, Los Angeles</td>
<td>Breast Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Todd R. Reilly, PhD</td>
<td>Johns Hopkins University (through 2006)</td>
<td>Breast Cancer</td>
<td>The Kimberly Lawrence Netter Breast Cancer Award</td>
</tr>
<tr>
<td></td>
<td>Katherine Ryman, PhD</td>
<td>University of Pittsburgh, Center for Vaccine Research</td>
<td>Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Vonderheide, MD, DPhil</td>
<td>University of Pennsylvania Abramson Cancer Center</td>
<td>Neuroblastoma</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Jeffrey S. Bartlett, PhD</td>
<td>The Research Institute at the National Children's Hospital (through 2012)</td>
<td>Ovarian Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrew M. Davidoff, MD</td>
<td>St.Jude Children's Research Hospital</td>
<td>Neuroblastoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas S. Griffith, PhD</td>
<td>University of Minnesota</td>
<td>Prostate Cancer</td>
<td></td>
</tr>
</tbody>
</table>
"Every dollar counts, and every donor makes a difference. Together we are saving lives. Thank you."

Barbara Gallagher, ACGT National Director of Philanthropy

---

**Founder’s Circle ($50,000+)**
- Geneve Corporation*
- Mr. and Mrs. Bill Fitzgerald*
- Mrs. Barbara Netter*
- Quinnipiac University*
- Swim Across America*
- The Wendy Walk

**President’s Circle ($25,000+)**
- The Lapin Foundation*
- Anne and Chau Khuong

**Pathfinders ($10,000+)**
- Alexandria Real Estate
- Guy Carpenter & Co.
- Cogan Family Foundation*
- Mr. and Mrs. Daniel Cummings
- Davies Ward Phillips & Vineberg LLP*
- Deloitte
- Mr. Donald Drelich
- Mr. and Mrs. Jeb Embree*
- Mr. and Mrs. Alan Englander*
- Mr. Peter Glicklich*
- Ms. Alva Greenberg*
- Mr. and Mrs. Peter Hearn*
- Drs. Aya and Eddy Jakobovits
- Ms. Joanna Karatzas*
- Mr. Jeffrey Keil*
- Mr. and Mrs. Edward Lampert
- Ms. Alexandra Landes
- Arlene and Reuben Mark*
- Joan and Ken Miller
- Mr. John Miller*
- Penn Medicine Development
- Regeneron

**Benefactors ($5,000+)**
- Mr. and Mrs. John Sites*
- Dr. Swan and Mr. Roy Thung*
- The Wasily Family Foundation
- Willis Towers Watson
- Mr. and Mrs. Charles Zoubek*

* Denotes Hall of Fame donor (5 consecutive years of giving)

---

“We are blown away by the phenomenal progress in research that the funds raised by SAA have made possible. More than that, we are elated by the lives that are being saved today. The 11-year ACGT-SAA partnership is making huge waves in the fight against cancer — our dedicated team is thrilled to be part of this fantastic journey!”

Michele Graham
Swim Across America Co-Chair
After losing my wife of 30 years to ovarian cancer in 2007, with the generosity of a friend and Board member at ACGT, a grant was awarded in my wife’s memory to Dr. Carl June for his research into immunotherapy. My children and I passionately share ACGT’s commitment to eradicating these dreadful diseases and we are grateful to play a small part in the future care and treatment of all types of cancer using gene therapies.

John Miller
Donor
Joan Miller & Linda Bernstein
Gene Therapy
Ovarian Cancer Award
Wendy Walk has contributed $300,000 towards a grant for ACGT Fellow, Dr. Crystal Mackall of Stanford University, whose focus is immunotherapy for sarcoma.

Mr. and Mrs. James Calabrese
CSL Behring
Mr. Martin Dickman
Lynda and Dean Duffy Family
Mr. Michael Englander
Mr. and Mrs. Stephen Fiverson
Mr. Ulises Flores
Ms. Andrea Fortunoff
Ms. Ashley Friedman
Mr. Richard Gervase
Mrs. Anne Gilhuly
Mr. and Mrs. Carl A. Goldman
Mr. and Mrs. Sheldon Gordon
Avrum Gray Family Fund
Ms. Barbara Hayes
Ms. Marilyn Howard
Mr. and Mrs. Thomas Hughes*
Mr. Kenneth Irvine
Mr. and Mrs. Allen Kaplan
Mr. Joseph A. Lander
Mr. and Mrs. Curtis Lane
Mr. Theodore Lobsenz*
Mr. William Mack
Mr. David Maidman
Mr. James Mannello
Mr. Tony Natale
Ms. Roxanne Rasmussen*
Mr. and Mrs. John Rosenberg
Mr. Martin Rosenman
Ms. Sabrina Leichter Rudin
Mr. and Mrs. Brian R. Schlier*
Mr. Andrew Semons
Mr. Louis Victor Senatore*
Terrence C. Shea
Mr. LeRoy Sluder, III
Ms. Kim Smith
Ms. Andrea Stark
Mr. and Mrs. Markley Suthers
Mr. and Mrs. James G. Tatum
Mr. Michael Thomas
Ms. Lisa Thung
Mr. David Treaster
Mr. and Mrs. Kevin Tyburski*
Umbrella Club of Fairfield County
Dr. Robert Vonderheide
Mr. and Mrs. Scott Welsh
Young Conaway Stargatt & Taylor

**Hall of Fame**
(5 consecutive years of giving, in addition to those previously marked with * above)

Jeremy Bradshaw
Mr. and Mrs. Peter Crumbine
Eugene Eanes
Ms. Tara Framer
Kathryn Gabler
Andreas Henke
Steven H. Kanofsky
Allen McCoy
Barbara L. Puszert
Mr. and Mrs. Richard Radcliffe
Sandra and Dennis Rosenzweig
Phyllis and Jay Schondorf
Hope and Harold Simkowitz
Anne and Ronald Simon
Mr. and Mrs. C. Winfield Swarr
Dr. Deborah and The Honorable Richard Tolchin
Thomas Walmsley
Mr. Austin James Warrin
Marylu and Jack Williams

We have made every effort to ensure the accuracy of our donor listings. If your name has been omitted or misprinted, please accept our sincere apologies and contact Jill Smith at jsmith@acgtfoundation.org or call 203.358.5055.

Donor listings reflect donations received between 9/1/2016 – 9/30/2017.

* Denotes Hall of Fame donor (5 consecutive years of giving)
When I joined the Board, cell and gene therapy against the ‘emperor of all maladies’ was a dream with a black eye. But, with 1 out of every 4 Americans contracting cancer in their lifetime, the cause for action was imperative. The innovative structure of an eminent group of scientists screening and ranking research proposals, and the contractual language allowing ACGT to participate in the success of subsequent research, made the commitment easy.

Now, our aspirations are being vindicated, and what we are seeing, I believe, is the tip of the iceberg of cell and gene therapies.

John Sites
ACGT Board Member since 2004
### BY THE NUMBERS...

- **$28.2 million** awarded for ACGT endeavors
- **$14.0 million** toward discovery and research
- **$14.2 million** toward translation into treatments

**100** Percent of donations that go directly toward research. Funding for administrative and fundraising costs is provided separately.

**55** Grants awarded

**36** Young Investigator Awards – Basic Research

**36** Different Institutions with ACGT Investigators

**19** Clinical Investigator Awards – Clinical Translation

**15** Number of Cancers Targeted by ACGT Researchers

**14** Scientific Advisory Council members

**1** The number of charitable organizations in the nation dedicated exclusively to cell and gene-based therapies for cancer.

---

“Less than 1% of NIH funding goes to discovery, but ACGT awards grants to young investigators seeking breakthrough solutions – these scientists are the future and many have gone on to become leaders in the field.”

Margaret Cianci
ACGT Executive Director

---

AN INVESTMENT IN ACGT SAVES LIVES NOW AND IN THE FUTURE
We believed from the start that gene therapy was the future for cancer treatment and private support for discovery research would be crucial to save lives. Now, even sooner than we imagined, progress is happening at the most prestigious medical institutions in the world and private funding is even more important to ensure the momentum.

Barbara Netter
Honorary Chairman and Co-Founder
In the longstanding war on cancer, new drugs and new ideas have abounded, but the basic approach has remained unchanged. Now, a whole new way of treatment is coming to fruition. Gene therapies attack the core of cancer first so the treatment has a greater chance of success with limited impact on other parts of the body.

Alliance for Cancer Gene Therapy has been, from the beginning, committed to supporting genetic medicine. Now, we see real results in real time. Genetic science, modern technology and great minds are the cure for cancer.

THE FUTURE IS NOW

96 Cummings Point Road
Stamford, CT 06902
203.358.5055
www.acgtfoundation.org